Aprogen pharmaceuticals,Inc.

KSE 003060.KS

Aprogen pharmaceuticals,Inc. EBIT Margin for the year ending December 31, 2023: -80.91%

Aprogen pharmaceuticals,Inc. EBIT Margin is -80.91% for the year ending December 31, 2023, a -482.18% change year over year. EBIT ratio is the ratio of EBIT to revenue, measuring a company's operating profitability without considering non-operating income or expenses.

Aprogen pharmaceuticals,Inc. EBIT Margin for the year ending December 31, 2022 was 21.17%, a 25.75% change year over year.
Aprogen pharmaceuticals,Inc. EBIT Margin for the year ending December 31, 2021 was 16.84%, a -40.87% change year over year.
Aprogen pharmaceuticals,Inc. EBIT Margin for the year ending December 31, 2020 was 28.48%, a 428.95% change year over year.
Aprogen pharmaceuticals,Inc. EBIT Margin for the year ending December 31, 2019 was -8.66%, a -160.90% change year over year.

Key data

Date	EBIT Margin	EPS (Basic)	EPS (Diluted)	Shares (Basic, Weighted)

KSE: 003060.KS

Aprogen pharmaceuticals,Inc.

CEO	Mr. Jeong-Chool Kim
IPO Date	Jan. 4, 2000
Location	South Korea
Headquarters	Halla Sigma Valley 442-2
Employees	377
Sector	Healthcare
Industries Pharmaceuticals Biotechnology Cosmetics Dental Care Drugstores & Retail Pharmacies Eyewear Personal Care Pet Food

Description

Aprogen pharmaceuticals,Inc. manufactures and sells pharmaceutical products primarily in South Korea. It offers approximately 200 types of medicines, including ethical and over the counter drugs. The company offers its drugs for transfusion, digestive system, osteoarthritis, skeletal muscle relaxants, NSAIDs, osteoporosis, circulatory system, endocrine, respiratory system, urinary system, depilatory, antihistamines and antiallergics, obesity, brain function, neurologics, and male pattern hair loss. It also provides anti-biotic, anti-fungal, anti-viral, anti-ulcerant, anti-epliepsy products; external agents; anti-cancer drugs; amino-acid nutrient transfusion agents; and cosmetics. The company was formerly known as Schnell Biopharmaceuticals, Inc. and changed its name to Aprogen pharmaceuticals,Inc. in April 2017. Aprogen pharmaceuticals,Inc. was founded in 1960 and is headquartered in Seongnam, South Korea.

Key trends

Past 5 years